EU Clinical Trial 2017-004776-56

Phase IIa Biomarker Study to Evaluate the Efficacy, Safety and Tolerability of AT-1 in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - the AT1-HCCAA study  Mar 6, 2019

Main objective of the trial: • Evaluate safety and tolerability of AT-1 administered orally in adults (ages 18 and over) with HCCAA with or without dementia symptoms • Assess dose-response relationship of AT-1 on HCCAA disease progression, including • Biomarker response from skin biopsies (reduction in cystatin C stain) • Assessment of cognitive status using dementia rating scales Evaluate safety and tolerability of AT-1 administered orally in adults (ages 18 and over) with HCCAA with or without dementia symptoms • Assess dose-response relationship of AT-1 on HCCAA disease progression, including • Biomarker response from skin biopsies (reduction in cystatin C stain) • Assessment of cognitive status using dementia rating scales

Parties

Investigators
Sponsors
Countries
US
Keywords
N-ACETYL CYSTEINE N-ACETYL CYSTEINE 600 MG

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.